Fairmount Healthcare Fund II L.P. 4

What Happened

• Fairmount Funds Management LLC (reported as a 10% owner) was granted an option to purchase 11,050 ordinary shares of Crescent BioPharma (CBIO) on 2026-06-02. The option was granted at $0.00 (i.e., a derivative award, not an open-market purchase), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-02; Filing date: 2026-06-03.
• Instrument: Option to acquire 11,050 shares (derivative award). Reported price: $0.00.
• Vesting: The option vests in full on the earlier of (i) June 2, 2027 or (ii) the Issuer’s next annual meeting of shareholders, subject to the reporting person’s continued service. (Footnote F1)
• Shares owned after transaction: Not specified in this Form 4 filing.
• Beneficial ownership/relationships (Footnote F2 & Remarks): Fairmount is the investment manager for Fairmount Healthcare Fund II LP; Peter Harwin and Tomas Kiselak are managers of Fairmount. They state they disclaim beneficial ownership except to the extent of pecuniary interest. The filing notes Fairmount and Fund II may be deemed a director by deputization because Peter Harwin serves on the Issuer’s board.
• Timeliness: Filed the day after the reported transaction; no late-filing indication in this record.

Context

• This was a grant of an option (a derivative award), not an immediate purchase of shares. The option must vest (by service/meeting date) before it can be converted into stock, so it does not represent immediate stock ownership or sale proceeds.
• As this involves a 10% institutional owner and includes manager/deputization disclosures, treat it as an institutional/managerial grant rather than a typical insider executive purchase or sale.